Ranolazine (monotherapy) vs placebo
Adverse events incidence · patients with stable angina pectoris
It is very uncertain whether ranolazine (monotherapy) changes adverse events incidence compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.5 [1.12, 2]3 studies · 947 participantsVery low